Leerink Swann Starts Puma Biotechnology (PBYI) at Outperform; Act II Has a Familiar Story Line
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Price: $9.11 --0%
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Leerink Swann initiates coverage on Puma Biotechnology (OTCBB: PBYI) with a Outperform. PT $20.00.
Analyst, Howard Liang, said, "Puma is a cancer-focused biotechnology company with an in-licensing model founded the same management team that successfully executed the same strategy with Cougar Biotechnology. Lead agent neratinib, a pan-HER tyrosine kinase inhibitor, is a late-stage compound for breast cancer currently in Phase II, after the rolling back of a Phase III program
following the transfer of the asset from Pfizer (NYSE: PFE). HER2+ breast cancer is a large market with over $5B in current sales of Roche’s Herceptin (>$5B), and GlaxoSmithKline's (NYSE: GSK) Tykerb (>$450M), another tyrosine kinase inhibitor (TKI) against HER2. Although Tykerb sales are currently relatively modest, it has been only approved for the metastatic setting and most of the Herceptin sales appear to come from the adjuvant setting."
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $ yesterday, with a 52 week range of $-$.
Analyst, Howard Liang, said, "Puma is a cancer-focused biotechnology company with an in-licensing model founded the same management team that successfully executed the same strategy with Cougar Biotechnology. Lead agent neratinib, a pan-HER tyrosine kinase inhibitor, is a late-stage compound for breast cancer currently in Phase II, after the rolling back of a Phase III program
following the transfer of the asset from Pfizer (NYSE: PFE). HER2+ breast cancer is a large market with over $5B in current sales of Roche’s Herceptin (>$5B), and GlaxoSmithKline's (NYSE: GSK) Tykerb (>$450M), another tyrosine kinase inhibitor (TKI) against HER2. Although Tykerb sales are currently relatively modest, it has been only approved for the metastatic setting and most of the Herceptin sales appear to come from the adjuvant setting."
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $ yesterday, with a 52 week range of $-$.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- William Blair Starts Tandem Diabetes Care (TNDM) at Outperform
- BNP Paribas Exane Starts NIQ Global Intelligence Plc (NIQ) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
